产品编号 | 产品名称 | 产品包装 | 产品价格 |
SM4136-10mM | 小檗碱(98%, HPLC) | 10mM×0.2ml | 74.00元 |
SM4136-25mg | 小檗碱(98%, HPLC) | 25mg | 100.00元 |
SM4136-100mg | 小檗碱(98%, HPLC) | 100mg | 340.00元 |
中文名 | 小檗碱 |
英文名 | Berberine |
中文别名 | 黄连素 |
英文别名 | Berbericine; Natural Yellow 18 |
来源 | 黄皮树Phellodendron chinense Schneid. |
化合物类型 | 生物碱(Alkaloids)>异喹啉生物碱>小檗碱型生物碱 |
化学式 | C20H18NO4+ |
分子量 | 336.36 |
CAS号 | 2086-83-1 |
纯度 | 98%, HPLC |
溶剂/溶解度 | DMSO: 41 mg/mL (121.9 mM) |
溶液配制 | 5mg加入1.49ml DMSO,或者每3.36mg加入1ml DMSO,配制成10mM溶液。 |
产品描述 | Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties. | ||||
信号通路 | Anti-microbial | ||||
靶点 | ROS | DNA topoisomerase | - | - | - |
IC50 | - | - | - | - | - |
体外研究 | Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase. Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM. | ||||
体内研究 | Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice. | ||||
临床实验 | NCT03609892: Gastric Ulcer|Chronic Gastritis|Gastric Cancer|Helicobacter Pylori Infection|Gastritis, Phase 4; NCT03029390:Prediabetes|Impaired Fasting Glucose|Impaired Glucose Tolerance, Phase 4; NCT04479202: Berberine|COVID-19, Phase 4; NCT02296021: Gastritis|Peptic Ulcer|Dyspepsia, Phase 4; NCT03198572: Non-alcoholic Steatohepatitis, Phase 4; NCT03548155: Schizophrenia|Therapeutics, Phase 4; NCT02633930: Gastritis|Peptic Ulcer|Dyspepsia, Phase 4; NCT03708549: Schizophrenia|Metabolic Syndrome|Berberine| Metformin, Phase 4; NCT02962245: Ulcerative Colitis, Phase 4; NCT03378934: Coronary Artery Disease|Percutaneous Coronary Intervention, Phase 4; NCT02808351: Diabetes Mellitus|Chronic Kidney Disease, Phase 4; |
1.Cai Y, et al. J Nat Med. 2014,68(1):53-62.
包装清单:产品编号 | 产品名称 | 包装 |
SM4136-10mM | 小檗碱(98%, HPLC) | 10mM×0.2ml |
SM4136-25mg | 小檗碱(98%, HPLC) | 25mg |
SM4136-100mg | 小檗碱(98%, HPLC) | 100mg |
- | 说明书 | 1份 |
-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。